Below is a list of all AbbVie clinical trials in Canada that you or someone you know might be interested in joining. Find what you’re looking for by using the filters to narrow down the results. You can also see the full list of conditions in which AbbVie deals here.
Clinical Trials
The purpose of this study is to evaluate Long-term outcomes following treatment with a combination of 2 active drugs with or without RBV in adults with genotype 1 Chronic Hepatitis C Virus (HCV) infection.
A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment withan active drug and to demonstrate the efficacy of the sustained virologic
A study to evaluate the efficacy and safety of an active drug in treatment-naïve participants with chronic hepatitis C virus (HCV) genotypes 1-6 infection and with an aspartate aminotransferase to platelet ratio index (APRI) of less than or equal to 1.
This was a Phase 3b, open-label, non-randomized, multicenter study to evaluate the efficacy and safety of an active drug in participants with chronic hepatitis C virus (HCV) genotype (GT) 1 - 6 infection without liver cirrhosis or with compensated liver
An open-label study to assess the pharmacokinetics (PK), safety, and efficacy of an active drug in pediatric participants divided into 4 age groups: 3 to
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of an active drug for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6 infection, with or without compensated
Hepatitis C Virus (HCV) infection is a global health problem. HCV mainly affects liver cells and causes the liver to become inflamed and damaged. This study will evaluate how safe and effective glecaprevir/pibrentasvir (GLE/PIB) is in adult and adolescent
